<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045913</url>
  </required_header>
  <id_info>
    <org_study_id>Yonsei University</org_study_id>
    <nct_id>NCT03045913</nct_id>
  </id_info>
  <brief_title>Genoss DES Prospective Multicenter Registry</brief_title>
  <official_title>Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of GENOSS Sirolimus-eluting Stent in Patients With Coronary Artery Disease (GENOSS Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Young Jin Youn, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genoss Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is a clinical post-market evaluation of the Genoss DES in subjects requiring&#xD;
      coronary revascularization with Drug Eluting Stents (DES).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) is the main stream of treatment of coronary artery&#xD;
      disease. Drug-eluting stents (DES) have dramatically reduced the rates of restenosis and&#xD;
      target lesion revascularization (TLR) compared with bare-metal stents (BMS). Newer-generation&#xD;
      DES with a durable polymer such as Xience (Abbott, US) and Resolute (Medtronic, US) were&#xD;
      widely used. However, the concern about late stent thrombosis due to hypersensitivity&#xD;
      reaction from the polymer is still existed. Recently, DES with a biodegradable polymer such&#xD;
      as Biomatrix (Biosensors, Switzerland), Nobori (Terumo, Japan), Orsiro (Biotronik,&#xD;
      Switzerland), and Synergy (Boston Scientific, US) was rapidly adopted and it is expected to&#xD;
      reduce the late stent thrombosis.&#xD;
&#xD;
      Recently, new biodegradable DES with thin struts was developed in South Korea. The Genoss DES&#xD;
      (Genoss, Korea) has an L-605 cobalt chromium (CoCr) platform with a strut thickness of about&#xD;
      70 µm and the stent is coated a combination of Sirolimus drug with concentration of&#xD;
      1.15µg/mm2 and an abluminal biodegradable PLA and PLGA polymers.&#xD;
&#xD;
      This study is conducted to evaluate efficacy and safety of Genoss DES in the treatment of&#xD;
      patients with coronary artery disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Device-oriented composite end point (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, any myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target-lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite end point</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of any death, any myocardial infarction, and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction not clearly attributable to a nontarget vessel</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Genoss DES</arm_group_label>
    <description>Subject implanted Genoss DES for coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genoss DES</intervention_name>
    <description>The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.</description>
    <arm_group_label>Genoss DES</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers patient population with all subjects requiring coronary revascularization with a&#xD;
        Drug Eluting Stent (DES)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is ≥ 19 years&#xD;
&#xD;
          -  Subject implanted Genoss DES within 1 month&#xD;
&#xD;
          -  Subject has signed informed consent for data release&#xD;
&#xD;
          -  Subject is geographically stable and willing to participate at all follow-up&#xD;
             assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject did not sign informed consent for data release&#xD;
&#xD;
          -  Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other&#xD;
             anticoagulation / antiplatelet therapy required for PCI, cobalt chromium, Sirolimus or&#xD;
             contrast media&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Subject with life expectancy less than 12 months&#xD;
&#xD;
          -  Subject with cardiogenic shock&#xD;
&#xD;
          -  Planned surgery within 12 months of PCI unless dual antiplatelet therapy will be&#xD;
             maintained&#xD;
&#xD;
          -  Currently participating in another study and primary endpoint is not reached yet.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon</state>
        <zip>220060</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Young Jin Youn, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Observational registry</keyword>
  <keyword>All-comers open label registry</keyword>
  <keyword>Genoss DES</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Stenting</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

